PROCURE Biobank, Canada

Registration Status: Pending

Objective: The PROCURE Biobank comprises biosamples and associated data from 2 082 prostate cancer patients enrolled between 2006 and 2012 in four University Hospitals of the Province of Québec. At enrolement, each patient was invited to fill a questionnaire to provide socio demographic as well as lifestyle data. From these, 96% (n= 2 007) underwent radical prostatectomy, biobanking (blood, serum, plasma, buffy coat, urine, normal and cancerous prostate tissues (frozen and FFPE)), longitudinal biosample collection and updated clinical data at periodical follow-up visits.

Registered Biobank Name	PROCURE Biobank
Biobank Leader	Alain Bergeron
Country	Canada
Email for biobank inquiries	ginette.mckercher@affiliate.mcgill.ca
Principal Investigator	Armen Aprikian
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).